Conferences

Improving Access to CAR T-Cell Therapies: Thomas G. Martin, MD

March 12th 2022

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed potential effects of cilta-cel's approval.

Managing Safety in Fitusiran Treatments of Hemophilia: Guy Young, MD

February 23rd 2022

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed mitigation strategies in trials and clinic.

Cilta-Cel in the Multiple Myeloma Treatment Landscape: Thomas G. Martin, MD

January 27th 2022

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies.

Expanding Study Populations of Cell Therapy in Sickle Cell Disease: Michael Grimley, MD

January 26th 2022

The medical director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's discussed data on ARU-1801 presented at ASH 2021.

Improving Outcomes in Hemophilia With Fitusiran: Guy Young, MD

January 22nd 2022

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed advantages of the siRNA therapeutic.

Cilta-Cel's Efficacy in Heavily Pretreated Patients With Multiple Myeloma: Thomas G. Martin, MD

January 19th 2022

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from the CARTITUDE-1 study presented at ASH 2021.

Sickle Cell Disease Cell Therapy Clinical Trial Enrolls First Patient

January 15th 2022

Details on the phase 1/2 CEDAR trial were presented at the 2021 ASH meeting.

Reducing Treatment Burden in Hemophilia: Guy Young, MD

January 12th 2022

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed improving outcomes in hemophilia with fitusiran.

Further Research With Tab-Cel in EBV+ Post-Transplant Lymphoproliferative Disease

January 12th 2022

AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed further research with tab-cel, including study 205.

Axi-Cel vs Tisa-Cel in R/R Diffuse Large B-Cell Lymphoma : Guenther Koehne, MD, PhD

January 10th 2022

The deputy director and chief of stem cell transplantation at Miami Cancer Institute discussed the study of axicabtagene ciloleucel vs tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma.